Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

One coronavirus vaccine to rule them all?

By Brian Buntz | February 10, 2021

A pan-coronavirus vaccine could be effective against SARS, MERS and SARS-CoV-2. [Image from VBI Vaccines]

As the rise of SARS-CoV-2 variants threatens to prolong the pandemic, a growing number of researchers are calling for the development of vaccines that can work on not just all SARS-CoV-2 variants but other coronaviruses as well.

The idea of a pan-coronavirus vaccine is not new. A handful of scientists have supported the concept of pan-coronavirus and universal flu vaccines for years. Last June, the privately-held company Immunovative Therapies (Jerusalem, Israel) announced it was working on a pan-viral vaccine. In November, NIAID announced it would offer funding for potential pan-coronavirus vaccine candidates.

A recent article in Nature espousing the idea elevates the idea further.

It’s easy to understand the appeal of the concept. A widely available pan-coronavirus vaccine could help stamp out future coronavirus pandemics and the common cold strains.

The economic benefits of such a vaccine would be considerable.

The productivity losses from the common cold and flu alone are monumental. Almost two decades ago, a team of researchers concluded that the cost of lost productivity from the common cold was approximately $25 billion in the U.S. annually. The firm Challenger, Gray and Christmas concluded in 2019 that the flu costs employers more than $17 billion. While COVID-19-related productivity losses may be difficult to calculate, the UN has concluded that they are “massive.”

Developing a pan-coronavirus vaccine, however, may prove challenging.

Coronaviruses are a relatively new target for vaccines. First identified in the 1960s, coronaviruses appeared to be more of an annoyance — causing common colds — than a real threat.

The emergence of SARS in 2002 and MERS in 2012 changed that impression, but those infections were more constrained than Ebola or Zika would be.

Last year, Cambridge, Mass.-based VBI Vaccines (NASDAQ: VBIV) created a pan-coronavirus vaccine candidate known as VBI-2901 designed to be effective against COVID-19, SARS and MERS. In animal experiments, the vaccine seemed to be effective against those three viruses and a coronavirus linked to the common cold in humans.

Researchers at Caltech recently published a study in Science highlighting the promise of nanoparticles in inducing an immune response to eight coronavirus types.

The Walter Reed Institute of Research and Saint Louis University also will attempt to develop pan-coronavirus vaccines.


Filed Under: clinical trials, Drug Discovery, Infectious Disease
Tagged With: coronavirus, covid-19
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE